• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Nomogram predicting cancer-specific mortality in patients with esophageal adenocarcinoma: a competing risk analysis.预测食管腺癌患者癌症特异性死亡率的列线图:一项竞争风险分析
J Thorac Dis. 2019 Jul;11(7):2990-3003. doi: 10.21037/jtd.2019.07.56.
2
Can a Nomogram Help to Predict the Overall and Cancer-specific Survival of Patients With Chondrosarcoma?列线图能否预测软骨肉瘤患者的总生存和癌症特异性生存?
Clin Orthop Relat Res. 2018 May;476(5):987-996. doi: 10.1007/s11999.0000000000000152.
3
Nomogram to predict cause-specific mortality of patients with rectal adenocarcinoma undergoing surgery: a competing risk analysis.列线图预测接受手术治疗的直肠腺癌患者的特定原因死亡率:竞争风险分析。
BMC Gastroenterol. 2022 Feb 10;22(1):57. doi: 10.1186/s12876-022-02131-1.
4
A convenient clinical nomogram for predicting the cancer-specific survival of individual patients with small-intestine adenocarcinoma.用于预测个体小肠腺癌患者癌症特异性生存的便捷临床列线图。
BMC Cancer. 2020 Jun 1;20(1):505. doi: 10.1186/s12885-020-06971-6.
5
Melanoma-specific mortality and competing mortality in patients with non-metastatic malignant melanoma: a population-based analysis.非转移性恶性黑色素瘤患者的黑色素瘤特异性死亡率和竞争性死亡率:一项基于人群的分析。
BMC Cancer. 2016 Jul 7;16:413. doi: 10.1186/s12885-016-2438-3.
6
Nomogram to Predict Cause-Specific Mortality in Patients With Surgically Resected Stage I Non-Small-Cell Lung Cancer: A Competing Risk Analysis.列线图预测手术切除的 I 期非小细胞肺癌患者的特定原因死亡率:竞争风险分析。
Clin Lung Cancer. 2018 Mar;19(2):e195-e203. doi: 10.1016/j.cllc.2017.10.016. Epub 2017 Oct 28.
7
Specific survival nomograms based on SEER database for small intestine adenocarcinoma.基于 SEER 数据库的小肠腺癌特定生存诺模图。
Ann Palliat Med. 2021 Jul;10(7):7440-7457. doi: 10.21037/apm-21-600. Epub 2021 Jul 14.
8
A competing risk nomogram predicting cause-specific mortality in patients with lung adenosquamous carcinoma.预测肺腺鳞癌患者特定原因死亡率的竞争风险列线图。
BMC Cancer. 2020 May 16;20(1):429. doi: 10.1186/s12885-020-06927-w.
9
A Competing-Risks Nomogram in Patients with Metastatic Pancreatic Duct Adenocarcinoma.转移性胰腺导管腺癌患者的竞争风险列线图
Med Sci Monit. 2019 May 18;25:3683-3691. doi: 10.12659/MSM.913533.
10
A competing risk nomogram for predicting cancer-specific death of patients with buccal mucosa cancer.预测颊黏膜癌患者癌症特异性死亡的竞争风险列线图
Oral Dis. 2021 May;27(4):900-910. doi: 10.1111/odi.13609. Epub 2020 Oct 1.

引用本文的文献

1
Development and validation of a prognostic nomogram for esophageal cancer patients based on SEER Asian population.基于 SEER 亚洲人群的食管癌患者预后列线图的建立和验证。
Sci Rep. 2024 Sep 14;14(1):21475. doi: 10.1038/s41598-024-72730-3.
2
Nomograms for prognosis prediction in esophageal adenocarcinoma: realities and challenges.食管腺癌预后预测的列线图:现状与挑战
Clin Transl Oncol. 2025 Feb;27(2):449-457. doi: 10.1007/s12094-024-03589-z. Epub 2024 Jul 31.
3
A Competing Risk Nomogram for Prediction of Prognosis in Patients With Primary Squamous Cell Thyroid Carcinoma.原发性鳞状细胞甲状腺癌患者预后预测的竞争风险列线图
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241254059. doi: 10.1177/15330338241254059.
4
Establishment and external validation of prognosis prediction nomogram for patients with distant metastatic intrahepatic cholangiocarcinoma: based on a large population.基于大样本量的远处转移性肝内胆管细胞癌患者预后预测列线图的建立和外部验证。
BMC Cancer. 2024 Feb 16;24(1):227. doi: 10.1186/s12885-024-11976-6.
5
Prognosis prediction in esophageal signet-ring-cell carcinoma: a competing risk analysis.食管印戒细胞癌预后预测:竞争风险分析。
BMC Gastroenterol. 2023 May 23;23(1):178. doi: 10.1186/s12876-023-02818-z.
6
Nomogram Based on Log Odds of Positive Lymph Nodes Predicting Cancer-Specific Survival in Patients With T3 and T4 Gallbladder Cancer After Radical Resection.基于阳性淋巴结对数优势比的列线图预测T3和T4期胆囊癌患者根治性切除术后的癌症特异性生存情况
Front Surg. 2021 Oct 27;8:675661. doi: 10.3389/fsurg.2021.675661. eCollection 2021.
7
Prognostic nomograms and risk-stratifying systems for predicting survival in patients with resected pT2-4aN0M0 esophageal carcinoma.用于预测接受手术切除的pT2-4aN0M0期食管癌患者生存情况的预后列线图和风险分层系统。
J Thorac Dis. 2021 Apr;13(4):2363-2377. doi: 10.21037/jtd-20-3393.
8
Lung Metastases in Newly Diagnosed Esophageal Cancer: A Population-Based Study.新诊断食管癌的肺转移:一项基于人群的研究。
Front Oncol. 2021 Feb 25;11:603953. doi: 10.3389/fonc.2021.603953. eCollection 2021.
9
A Predicting Nomogram for Mortality in Patients With COVID-19.用于预测 COVID-19 患者死亡率的列线图模型。
Front Public Health. 2020 Aug 11;8:461. doi: 10.3389/fpubh.2020.00461. eCollection 2020.

本文引用的文献

1
Sex differences in the prognosis after surgery for esophageal squamous cell carcinoma and adenocarcinoma.食管鳞癌和腺癌手术后预后的性别差异。
Int J Cancer. 2019 Mar 15;144(6):1284-1291. doi: 10.1002/ijc.31840. Epub 2018 Oct 31.
2
Survival Disparities by Race and Ethnicity in Early Esophageal Cancer.早期食管癌中种族和民族的生存差异。
Dig Dis Sci. 2018 Nov;63(11):2880-2888. doi: 10.1007/s10620-018-5238-6. Epub 2018 Aug 14.
3
Prognosis of oesophageal adenocarcinoma and squamous cell carcinoma following surgery and no surgery in a nationwide Swedish cohort study.瑞典一项全国性队列研究中,手术与非手术治疗后食管腺癌和鳞状细胞癌的预后情况。
BMJ Open. 2018 May 10;8(5):e021495. doi: 10.1136/bmjopen-2018-021495.
4
Quantitative association between body mass index and the risk of cancer: A global Meta-analysis of prospective cohort studies.体重指数与癌症风险的定量关联:前瞻性队列研究的全球荟萃分析。
Int J Cancer. 2018 Oct 1;143(7):1595-1603. doi: 10.1002/ijc.31553. Epub 2018 May 13.
5
New Screening Techniques in Barrett's Esophagus: Great Ideas or Great Practice?巴雷特食管的新型筛查技术:伟大构想还是伟大实践?
Gastroenterology. 2018 May;154(6):1594-1601. doi: 10.1053/j.gastro.2018.03.031. Epub 2018 Mar 23.
6
Disparities in survival after trimodality therapy for esophageal adenocarcinoma.食管腺癌三联疗法后的生存差异。
Dis Esophagus. 2018 Sep 1;31(9). doi: 10.1093/dote/doy020.
7
Association between circulating levels of sex steroid hormones and esophageal adenocarcinoma in the FINBAR Study.芬兰男性乳腺癌风险评估(FINBAR)研究中性类固醇激素循环水平与食管腺癌之间的关联。
PLoS One. 2018 Jan 17;13(1):e0190325. doi: 10.1371/journal.pone.0190325. eCollection 2018.
8
Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01).晚期食管癌姑息性放化疗与单纯放疗吞咽困难比较:一项多中心随机对照试验(TROG 03.01)。
Lancet Gastroenterol Hepatol. 2018 Feb;3(2):114-124. doi: 10.1016/S2468-1253(17)30363-1. Epub 2017 Dec 14.
9
Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants.基于流行病学因素和基因变异确定巴雷特食管和食管腺癌的风险
Gastroenterology. 2018 Apr;154(5):1273-1281.e3. doi: 10.1053/j.gastro.2017.12.003. Epub 2017 Dec 13.
10
Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy.大型心血管临床试验中的竞争风险分析:APEX子研究
Pharm Stat. 2017 Nov;16(6):445-450. doi: 10.1002/pst.1823. Epub 2017 Aug 24.

预测食管腺癌患者癌症特异性死亡率的列线图:一项竞争风险分析

Nomogram predicting cancer-specific mortality in patients with esophageal adenocarcinoma: a competing risk analysis.

作者信息

Wu Xi-Xi, Chen Ren-Pin, Chen Rui-Cong, Gong Hong-Peng, Wang Bin-Feng, Li Ya-Ling, Lin Xin-Ran, Huang Zhi-Ming

机构信息

Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.

Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.

出版信息

J Thorac Dis. 2019 Jul;11(7):2990-3003. doi: 10.21037/jtd.2019.07.56.

DOI:10.21037/jtd.2019.07.56
PMID:31463129
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6687980/
Abstract

BACKGROUND

Many factors are reported to be related to the prognosis of patients with esophageal adenocarcinoma (EAC), but few reliable and straightforward tools for clinicians to estimate individual mortalities have been developed. This study aimed to evaluate the probability of cancer-specific death for patients with EAC and to build nomograms for predicting long-term cancer-specific mortality and overall mortality for EAC patients.

METHODS

Between 2004 and 2013, a total of 20,623 patients were identified from the surveillance, epidemiology, and end results (SEER) database and randomly divided into training (N=14,436) and validation (N=6,187) cohorts. The cumulative incidence functions (CIFs) of EAC-specific death and other causes were evaluated at the 1st, 3rd, and 5th year after diagnosis. We integrated the significant prognostic factors to construct nomograms and subjected them to internal and external validation.

RESULTS

The CIFs of EAC-specific survival at 1, 3, and 5 years after diagnosis were 60.9%, 37.1%, and 31.3%, respectively. Predictors for cancer-specific mortality for EAC comprised tumor grade, tumor extension, the involvement of lymph nodes, distant metastasis, surgery of primary site, insurance recode, and marital status. For overall mortality, it also included the predictor of age at diagnosis. The nomograms were well-calibrated and had good discriminative ability with concordance indexes (c-indexes) of 0.733, 0.728, and 0.728 for 1-, 3- and 5-year prognosis prediction of EAC-specific mortality respectively, and 0.726, 0.720, 0.719 for 1-, 3-, and 5-year prognosis prediction of overall mortality respectively.

CONCLUSIONS

We proposed and validated the effective and convenient nomograms to predict cancer-specific mortality and the overall mortality for patients with EAC, which only require the basic information available in clinical practice.

摘要

背景

据报道,许多因素与食管腺癌(EAC)患者的预后相关,但目前针对临床医生估算个体死亡率的可靠且简便的工具却很少。本研究旨在评估EAC患者癌症特异性死亡的概率,并构建列线图以预测EAC患者的长期癌症特异性死亡率和总死亡率。

方法

2004年至2013年间,从监测、流行病学和最终结果(SEER)数据库中识别出总共20623例患者,并将其随机分为训练队列(N = 14436)和验证队列(N = 6187)。在诊断后的第1、3和5年评估EAC特异性死亡和其他原因的累积发病率函数(CIF)。我们整合了显著的预后因素来构建列线图,并对其进行内部和外部验证。

结果

诊断后1、3和5年EAC特异性生存的CIF分别为60.9%、37.1%和31.3%。EAC癌症特异性死亡率的预测因素包括肿瘤分级、肿瘤扩展、淋巴结受累、远处转移、原发部位手术、保险编码和婚姻状况。对于总死亡率,它还包括诊断时年龄这一预测因素。列线图校准良好,具有良好的辨别能力,EAC特异性死亡率1年、3年和5年预后预测的一致性指数(c指数)分别为0.733、0.728和0.728,总死亡率1年、3年和5年预后预测的c指数分别为0.726、0.720和0.719。

结论

我们提出并验证了有效且便捷的列线图,用于预测EAC患者的癌症特异性死亡率和总死亡率,这些列线图仅需要临床实践中可用的基本信息。